BioPorto Future Growth
Future criteria checks 2/6
BioPorto's earnings are forecast to decline at 27.8% per annum while its annual revenue is expected to grow at 31.7% per year. EPS is expected to decline by 17.3% per annum.
Key information
-27.8%
Earnings growth rate
-17.3%
EPS growth rate
Biotechs earnings growth | 40.8% |
Revenue growth rate | 31.7% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 31 Oct 2024 |
Recent future growth updates
Recent updates
We're Hopeful That BioPorto (CPH:BIOPOR) Will Use Its Cash Wisely
Oct 22We Think BioPorto (CPH:BIOPOR) Needs To Drive Business Growth Carefully
Dec 25We Think BioPorto (CPH:BIOPOR) Needs To Drive Business Growth Carefully
Jun 28We're Hopeful That BioPorto (CPH:BIOPOR) Will Use Its Cash Wisely
Feb 27Companies Like BioPorto (CPH:BIOPOR) Are In A Position To Invest In Growth
Oct 19We're Keeping An Eye On BioPorto's (CPH:BIOPOR) Cash Burn Rate
Jun 15Is BioPorto (CPH:BIOPOR) In A Good Position To Deliver On Growth Plans?
Feb 17Here's Why We're Not Too Worried About BioPorto's (CPH:BIOPOR) Cash Burn Situation
Oct 16Companies Like BioPorto (CPH:BIOPOR) Are In A Position To Invest In Growth
May 28BioPorto A/S' (CPH:BIOPOR) Path To Profitability
Mar 01We Think BioPorto (CPH:BIOPOR) Needs To Drive Business Growth Carefully
Jan 24A Look At BioPorto's (CPH:BIOPOR) CEO Remuneration
Dec 20The BioPorto A/S (CPH:BIOPOR) Analysts Have Been Trimming Their Sales Forecasts
Nov 23BioPorto A/S (CPH:BIOPOR) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Nov 21Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2025 | 52 | -90 | N/A | N/A | 1 |
12/31/2024 | 40 | -73 | N/A | N/A | 1 |
9/30/2024 | 35 | -61 | -69 | -69 | N/A |
3/31/2024 | 32 | -54 | -50 | -50 | N/A |
12/31/2023 | 31 | -56 | -55 | -55 | N/A |
9/30/2023 | 33 | -70 | -69 | -69 | N/A |
6/30/2023 | 30 | -78 | -63 | -63 | N/A |
3/31/2023 | 31 | -75 | -62 | -62 | N/A |
12/31/2022 | 29 | -76 | -53 | -52 | N/A |
9/30/2022 | 27 | -68 | -51 | -51 | N/A |
6/30/2022 | 27 | -62 | -59 | -58 | N/A |
3/31/2022 | 25 | -59 | -61 | -60 | N/A |
12/31/2021 | 24 | -57 | -65 | -65 | N/A |
9/30/2021 | 25 | -54 | -59 | -58 | N/A |
6/30/2021 | 24 | -60 | -48 | -47 | N/A |
3/31/2021 | 25 | -62 | -44 | -43 | N/A |
12/31/2020 | 23 | -62 | -37 | -36 | N/A |
9/30/2020 | 22 | -64 | -43 | -42 | N/A |
6/30/2020 | 24 | -68 | -55 | -55 | N/A |
3/31/2020 | 25 | -69 | -62 | -61 | N/A |
12/31/2019 | 27 | -70 | -61 | -60 | N/A |
9/30/2019 | 29 | -61 | -53 | -51 | N/A |
6/30/2019 | 28 | -51 | -45 | -44 | N/A |
3/31/2019 | 27 | -43 | -40 | -39 | N/A |
12/31/2018 | 26 | -38 | -39 | -38 | N/A |
9/30/2018 | 24 | -38 | -40 | -39 | N/A |
6/30/2018 | 25 | -36 | N/A | -38 | N/A |
3/31/2018 | 24 | -35 | N/A | -36 | N/A |
12/31/2017 | 25 | -32 | N/A | -29 | N/A |
9/30/2017 | 25 | -29 | N/A | -26 | N/A |
6/30/2017 | 23 | -27 | N/A | -25 | N/A |
3/31/2017 | 21 | -26 | N/A | -21 | N/A |
12/31/2016 | 21 | -23 | N/A | -20 | N/A |
9/30/2016 | 20 | -21 | N/A | -21 | N/A |
6/30/2016 | 20 | -16 | N/A | -20 | N/A |
3/31/2016 | 21 | -12 | N/A | -18 | N/A |
12/31/2015 | 20 | -11 | N/A | -17 | N/A |
9/30/2015 | 20 | -11 | N/A | -15 | N/A |
6/30/2015 | 19 | -12 | N/A | -14 | N/A |
3/31/2015 | 18 | -13 | N/A | -14 | N/A |
12/31/2014 | 19 | -13 | N/A | -16 | N/A |
9/30/2014 | 18 | -15 | N/A | -14 | N/A |
6/30/2014 | 19 | -19 | N/A | -16 | N/A |
3/31/2014 | 18 | -20 | N/A | -17 | N/A |
12/31/2013 | 17 | -22 | N/A | -17 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BIOPOR is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: BIOPOR is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: BIOPOR is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: BIOPOR's revenue (31.7% per year) is forecast to grow faster than the Danish market (11.3% per year).
High Growth Revenue: BIOPOR's revenue (31.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if BIOPOR's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/19 01:50 |
End of Day Share Price | 2024/12/19 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
BioPorto A/S is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
null null | Brookline Capital Markets |
Jyoti Prakash | Edison Investment Research |
Yi Chen | H.C. Wainwright & Co. |